Partnership to Advance Pharmacogenomics in Singapore and Indonesia

May 2022

On April 19, MGI, a world-leading life science company, announced partnership with Nalagenetics (NALA). The aim of the partnership is to co-develop low coverage whole genome sequencing for risk prediction and pharmacogenomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI’s sequencing devices and products.

The collaboration plans to use NALA’ Clinical Decision Support, a software medical device, to  analyze whole genome sequencing data sets generated by MGI’s DNBSEQTM  sequencing platform*, and generate clinical-grade reports for pharmacogenomics and  polygenic risk scores. Although NGS is an effective way to capture a large  amount of genomic information to guide and tailor clinical management and treatment,1 NGS  workflows are complicated to adopt in clinical settings. NALA is dedicated to help  implement clinical genetic testing in Southeast Asia with strong expertise in pharmacogenetics, assay development, and AI-linked genetics analysis for pharmacological phenotypes and risk prediction.

More and more hospitals today are adopting sequencing for personalization of medicine in  oncology, cardiovascular conditions, and others. According to Levana Sani, CEO of Nalagenetics, “One of the biggest challenges is  recommending follow up action that makes sense for the local market, for example list of  alternative therapies and screening procedures that lead to cost-effectiveness. We are glad to work with MGI to co-develop products and offer services to answer local needs”.


(Source: MGI)

Our Services

Orissa International provides consulting services to companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 distributors, resellers, and system integrators, built through advising and guiding more than 5,000 companies with their market expansion into Singapore, Malaysia, Indonesia, Thailand, Vietnam and the Philippines over the last 25 years.